Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).
Ophthalmology
; 127(9): 1201-1210, 2020 09.
Article
in En
| MEDLINE
| ID: mdl-32402554
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Recombinant Fusion Proteins
/
Macular Edema
/
Angiogenesis Inhibitors
/
Receptors, Vascular Endothelial Growth Factor
/
Diabetic Retinopathy
/
Bevacizumab
/
Ranibizumab
Type of study:
Clinical_trials
/
Etiology_studies
/
Guideline
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Ophthalmology
Year:
2020
Document type:
Article